Congress Increases Funding for Type 1 Diabetes Research Amid Access Concerns

On February 3, 2023, Congress renewed the Special Diabetes Program (SDP), boosting annual federal funding for Type 1 diabetes (T1D) research from $160 million to $200 million through the end of the year. This bipartisan initiative secures over $3.5 billion for diabetes research since the program’s inception in 1997. While this funding increase is promising for future innovations, questions remain about the actual benefits for those living with T1D.

Many patients depend on advanced health technologies for daily management of their condition. Continuous Glucose Monitors (CGMs), for instance, alert users before their blood sugar levels become dangerously low, enabling safer sleep, improved focus in academic and professional environments, and increased participation in physical activities. For individuals like those in the T1D community, these tools represent essential safeguards rather than mere conveniences.

In countries with centralized healthcare systems, such as Australia, access to these devices is often fully subsidized. However, patients in the United States face stark contrasts. The cost of a monthly supply of CGMs can reach $1,599 at a local pharmacy, whereas the same supply may cost nothing in other countries. These discrepancies highlight the impact of policy decisions on healthcare access.

The SDP has played a critical role in advancing diabetes care over the past 25 years, leading to significant developments such as CGMs, insulin pumps, and islet cell transplantation. These technologies have transformed life for the more than two million Americans living with T1D, offering them greater independence and reducing the risk of severe complications. However, a pressing question arises: who ultimately benefits from the research funded by Congress?

T1D management requires continuous attention and reliable healthcare access. Older treatments, which involved multiple daily finger pricks, insulin injections, and restrictive diets, made daily life challenging, particularly for individuals managing fluctuating work schedules or housing instability. Newer technologies, while offering considerable improvements, also come with high costs. A new insulin pump can exceed $8,000 out of pocket, not including annual expenses of $2,000 to $6,000 for ongoing supplies.

Even with insurance coverage, patients often encounter numerous administrative hurdles, such as prior authorizations and prescription renewals. These challenges create instability for patients, leading many to ration their supplies. The choice between essential medications and basic living expenses, like rent, should not be a reality for those affected by T1D.

Furthermore, even FDA-approved technologies struggle with distribution challenges. While the National Institutes of Health (NIH) manages SDP funding, issues like cost barriers and inconsistent insurance coverage continue to hinder access. Social determinants, including race and income, also play a significant role in healthcare disparities. For example, Black patients with T1D are less likely to receive essential technologies like CGMs compared to their non-Black counterparts.

California’s reputation as a hub for biomedical innovation, especially in Silicon Valley, emphasizes the importance of addressing these issues. Stanford University, which benefits directly from federal research funding, has the opportunity to bridge the gap between scientific advancements and their practical application in healthcare.

While the renewed funding for diabetes research is commendable, it does not address the underlying issues of access and affordability. Advocacy for enhanced distribution of innovations is essential. The NIH is responsible for guiding research priorities, but without a commitment to equitable access, the benefits of scientific progress may only reach those with adequate financial resources.

The bipartisan support for diabetes research should not overshadow the critical need for reform in pricing and insurance practices. If the goal is not only scientific advancement but also improved health outcomes for all, equitable access must be prioritized alongside innovation. Patients deserve not just the promise of future breakthroughs, but immediate access to affordable technologies that can enhance their quality of life.